ACTEMRA (also known as tocilizumab)
Actemra is an antibody that binds to Interleukin-6 (IL-6). Il-6 is a key component of many inflammatory pathologies such as Rheumatoid Arthritis.
- Moderate to severe rheumatoid arthritis who did not respond adequately to disease modifying anti-rheumatic drugs, like Methotrexate.
- Giant cell arteritis.
- Polyarticular juvenile idiopathic arthritis (Age >= 2)
- Systemic juvenile idiopathic arthritis (Age >= 2)
Patients with active infection should not be administered Actemra. Patients with low platelet count, low neutrophil count, elevated liver enzymes or patients with history of diverticulitis currently on NSAID and steroid therapy should ask their physician before starting Actemra.
Actemra is typically administered as a single intravenous infusion over 1 hour and repeated every 4 weeks.